
Integer, a medical device contract development and manufacturing organization (CDMO), announced the completion of its acquisition by an affiliate of investment funds managed by KKR in a transaction valued at an enterprise value of approximately $5.7 billion.
The deal was announced on August 3, 2026, and was approved by Integer stockholders on October 21, 2026. Under the terms of the transaction, Integer stockholders will receive $127 per share in cash. With the completion of the transaction, Integer’s common stock has ceased trading and will no longer be listed on the New York Stock Exchange.
“Today marks an exciting new chapter for Integer, our associates, customers, and the patients we collectively serve,” said Payman Khales, Integer’s President and CEO. “Integer has built a reputation as a trusted partner to the world’s leading medical device companies and emerging innovators through our relentless focus on quality, customer service, and innovation. Together with KKR, we are well positioned to accelerate our growth strategy, further invest in our people, capabilities and technologies, and continue delivering the expertise and solutions that help our customers bring life-enhancing and life-saving devices to patients around the world.”
“We are pleased to officially welcome Integer to the KKR portfolio and look forward to building on the Company’s strong foundation alongside Payman and the management team,” said Max Lin, Partner at KKR. “We see significant opportunities to leverage our resources and expertise to support Integer’s next phase of growth, expand its capabilities and strengthen its position as a trusted partner to the global medical device industry.”






















